DE3505572A1 - Injizierbare loesung, besonders zur behandlung von ketose, und verfahren zur herstellung derselben - Google Patents
Injizierbare loesung, besonders zur behandlung von ketose, und verfahren zur herstellung derselbenInfo
- Publication number
- DE3505572A1 DE3505572A1 DE19853505572 DE3505572A DE3505572A1 DE 3505572 A1 DE3505572 A1 DE 3505572A1 DE 19853505572 DE19853505572 DE 19853505572 DE 3505572 A DE3505572 A DE 3505572A DE 3505572 A1 DE3505572 A1 DE 3505572A1
- Authority
- DE
- Germany
- Prior art keywords
- weight
- glucose
- nicotinic acid
- injectable solution
- ketosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000007976 Ketosis Diseases 0.000 title claims description 14
- 230000004140 ketosis Effects 0.000 title claims description 14
- 229940102223 injectable solution Drugs 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 32
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 16
- 239000008103 glucose Substances 0.000 claims description 16
- 229960003512 nicotinic acid Drugs 0.000 claims description 16
- 235000001968 nicotinic acid Nutrition 0.000 claims description 16
- 239000011664 nicotinic acid Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000654 additive Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 5
- 239000000243 solution Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 241001494479 Pecora Species 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 229930003270 Vitamin B Natural products 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- -1 Glucose sodium chloride potassium chloride calcium chloride magnesium chloride potassium iodide L-lysine hydrochloride DL-methionine L-valine L-cysteine hydrochloride sodium glutamate Chemical compound 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 229910001615 alkaline earth metal halide Inorganic materials 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU841091A HU191598B (en) | 1984-03-20 | 1984-03-20 | Method for the preparation of injection solution suitable preferably against cathosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3505572A1 true DE3505572A1 (de) | 1985-09-26 |
| DE3505572C2 DE3505572C2 (enExample) | 1989-04-20 |
Family
ID=10952793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19853505572 Granted DE3505572A1 (de) | 1984-03-20 | 1985-02-18 | Injizierbare loesung, besonders zur behandlung von ketose, und verfahren zur herstellung derselben |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS60260510A (enExample) |
| BE (1) | BE901959A (enExample) |
| DE (1) | DE3505572A1 (enExample) |
| FR (1) | FR2561522B1 (enExample) |
| GB (1) | GB2157561B (enExample) |
| HU (1) | HU191598B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE9111598U1 (de) * | 1991-09-18 | 1993-01-28 | Helga Kellermann Mineralgetränke, 5063 Overath | Futtermittel |
| US5767123A (en) * | 1994-11-17 | 1998-06-16 | Tanabe Seiyaku Co., Ltd. | Total parenteral nutrition solution containing water-soluble vitamin B |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2245491A (en) * | 1990-06-25 | 1992-01-08 | Medvet Science Pty Ltd | Inhibition of metabolic oxalate formation |
| GB9216460D0 (en) * | 1992-08-03 | 1992-09-16 | Lilly Industries Ltd | Veterinary method |
| JP2001114681A (ja) * | 1999-10-18 | 2001-04-24 | Ajinomoto Co Inc | ケトーシス改善剤 |
| RU2238728C1 (ru) * | 2003-05-06 | 2004-10-27 | Открытое акционерное общество "Новосибхимфарм" | Способ получения раствора никотиновой кислоты для инъекций |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD60477A (enExample) * | ||||
| GB500770A (en) * | 1937-09-30 | 1939-02-15 | Vitamol Inc | Improvements in or relating to vitamin compositions for use in feeding poultry and livestock, and methods of making the same |
| FR1350101A (fr) * | 1962-12-13 | 1964-01-24 | Produit pour l'alimentation des animaux |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE739613A (enExample) * | 1968-10-03 | 1970-03-02 | ||
| GB1289096A (enExample) * | 1968-10-03 | 1972-09-13 | ||
| ZA73288B (en) * | 1972-02-25 | 1973-10-31 | Hoffmann La Roche | Mineral salts containing preparation |
| AU7003774A (en) * | 1974-06-13 | 1975-12-18 | Otsuka Pharma Co Ltd | Parenteral feeding method |
| JPS5535049A (en) * | 1978-09-04 | 1980-03-11 | Otsuka Pharmaceut Factory Inc | Amino acid transfusion for cancerous patient |
-
1984
- 1984-03-20 HU HU841091A patent/HU191598B/hu not_active IP Right Cessation
-
1985
- 1985-02-18 DE DE19853505572 patent/DE3505572A1/de active Granted
- 1985-03-18 BE BE1/11215A patent/BE901959A/fr not_active IP Right Cessation
- 1985-03-19 FR FR8504016A patent/FR2561522B1/fr not_active Expired
- 1985-03-20 GB GB08507176A patent/GB2157561B/en not_active Expired
- 1985-03-20 JP JP60054707A patent/JPS60260510A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD60477A (enExample) * | ||||
| GB500770A (en) * | 1937-09-30 | 1939-02-15 | Vitamol Inc | Improvements in or relating to vitamin compositions for use in feeding poultry and livestock, and methods of making the same |
| FR1350101A (fr) * | 1962-12-13 | 1964-01-24 | Produit pour l'alimentation des animaux |
Non-Patent Citations (3)
| Title |
|---|
| DE-Buch: G.Ehrhart, H.Ruschig, Arzneimittel, Bd.2, Weinheim/Bergstr., 1972, S.429 * |
| GB-B.: Martindale, The Extra Pharmacopoeia, 26. Ed., S.1966-1967 * |
| HELWIG, B.: Moderne Arzneimittel, 5.Aufl., 1980, S.619 u. 625 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE9111598U1 (de) * | 1991-09-18 | 1993-01-28 | Helga Kellermann Mineralgetränke, 5063 Overath | Futtermittel |
| US5767123A (en) * | 1994-11-17 | 1998-06-16 | Tanabe Seiyaku Co., Ltd. | Total parenteral nutrition solution containing water-soluble vitamin B |
Also Published As
| Publication number | Publication date |
|---|---|
| HU191598B (en) | 1987-03-30 |
| FR2561522B1 (fr) | 1988-10-14 |
| GB8507176D0 (en) | 1985-04-24 |
| GB2157561B (en) | 1988-01-20 |
| HUT37035A (en) | 1985-11-28 |
| GB2157561A (en) | 1985-10-30 |
| DE3505572C2 (enExample) | 1989-04-20 |
| BE901959A (fr) | 1985-09-18 |
| FR2561522A1 (fr) | 1985-09-27 |
| JPS60260510A (ja) | 1985-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69328497T2 (de) | Verfahren zur steigerung der wirksamkeit der futterverwertung bei tieren | |
| AT391980B (de) | Verfahren zur erhoehung der gewichtszunahme von schweinen oder milchwirtschaftlich genutzten kuehen | |
| DE3525902A1 (de) | Antibakterielle nahrungsmittelzusammensetzungen, deren herstellung und verwendung | |
| DE2849226A1 (de) | Verfahren zur wachstumsfoerderung von gefluegel, mittel zu seiner durchfuehrung und deren herstellung | |
| DE3119051A1 (de) | Mittel zur behandlung der augen | |
| DE69838432T2 (de) | Trinkwasserzusatz für Vögel sowie Verfahren zur Verabreichung desselben | |
| DE2036114B2 (de) | Wäßriges Tetramisolpräparat | |
| DE2822789C2 (de) | N-Acetyl-DL-methionin-(p-acetylaminophenyl)-ester, Verfahren zu seiner Herstellung und seine Verwendung | |
| EP1465641B1 (de) | Arzneimittel enthaltend deuterium zur behandlung der zuckerkrankheit | |
| DE3013000C2 (de) | Pansendurchtretendes Futterzusatzmittel für Wiederkäuer und dessen Verwendung zur Fütterung von Wiederkäuern | |
| DE3618931A1 (de) | Futterzusatz, verfahren zu dessen zubereitung und verfahren zu dessen verwendung | |
| DE3137125A1 (de) | Verwendung von pyridoxin-(alpha)-ketoglutarat fuer die prophylaxe der hyperlactacidaemie | |
| DE2347225C3 (de) | Verwendung von Spurenelementen bei der Injektionstherapie | |
| DE3505572A1 (de) | Injizierbare loesung, besonders zur behandlung von ketose, und verfahren zur herstellung derselben | |
| DE3520010A1 (de) | Verfahren und mittel zur optimierung der assimilation der futtermittel durch wiederkaeuer bei der mast | |
| DE69931492T2 (de) | L-calcium-pidolat enthaltende zusammensetzung für legegeflügel | |
| EP0107161A2 (de) | Mittel und Verfahren zur Optimierung der Gewebemasse von Organen innerhalb der genetischen Schwankungsbreite bei Menschen und Tieren | |
| EP0125322B1 (de) | Verfahren zur Anwendung ergotroper Wirkstoff-Kombinationen in der Aufzucht und Mast von Nutztieren | |
| DE3705186A1 (de) | Veterinaermedizinische zubereitungen | |
| DE68910220T2 (de) | Veterinäre Zusammensetzungen zur Verwendung gegen Endoparasiten und Verfahren zu ihrer Herstellung. | |
| DD202383A5 (de) | Futterkonzentrate, futterzusaetze oder futter mit antimikrobiellen und/oder gewichtssteigernden eigenschaften | |
| DE2644197A1 (de) | Verfahren und mittel zur bekaempfung der diarrhoe bei monogastrischen tieren und neugeborenen wiederkaeuern | |
| DE2846956A1 (de) | Futterzusatz auf harnstoffbasis | |
| EP0160115B1 (de) | Wachstumsstimulierender Futterzusatz für Nutztiere | |
| DE1692463A1 (de) | Stimulans fuer das Wachstum und die Entwicklung von Tieren,von Gefluegel sowie Verfahren zur Herstellung desselben |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8101 | Request for examination as to novelty | ||
| 8105 | Search report available | ||
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |